Profile: Catalyst Pharmaceutical Partners Inc (CPRX.OQ)
26 Dec 2014
Catalyst Pharmaceutical Partners, Inc., incorporated in July 2006, is a development-stage biopharmaceutical company. The Company is focused on the development and commercialization of prescription drugs targeting addiction diseases and disorders of the central nervous system with a focus on the treatment of addiction and epilepsy. As of December 31, 2011, the Company had two drugs in development: CPP-109 and CPP-115. of December 31, 2011, it was evaluating its drug candidate, CPP-109 for the treatment of cocaine addiction. As of December 31, 2011, the Company was in the early stages of developing CPP-115, another GABA aminotransferase inhibitor. It has identified two market opportunities that can be exploited by pharmacotherapies that inhibit GABA-aminotransferase (GABA-AT): drug addiction and epilepsy.
CPP-115 is used for the treatment of addiction and epilepsy. CPP-109 (vigabatrin) is used to treat addiction. CPP-115, like vigabatrin (CPP-109), is a GABA-AT inhibitor, and the Company is developing it for both drug addiction (cocaine addiction) and epilepsy (specifically, infantile spasms and complex partial seizures). As of December 31, 2011, the Company is involved in the product development activities: the Food and Drug Administration (FDA) has accepted its Investigational New Drug Application (IND) for CPP-115; it has commenced an initial Phase I(a) clinical study evaluating the safety of CPP-115 in healthy volunteers; and it is jointly conducting with the National Institute on Drug Abuse (NIDA) and the Veterans Administration (VA) a U.S. Phase II(b) clinical trial of CPP-109.
The Company competes with Pfizer, J&J, UCB, Abbott, GSK, Roche and Novartis.
Catalyst Pharmaceutical Partners Inc
355 Alhambra Cir Ste 1500
CORAL GABLES FL 33134-5038